Gyre Therapeutics, Inc. - צמיחת הכנסות ב-12 חודשים נגררים GYRE

Gyre Therapeutics, Inc. (GYRE) relies on external CMO and CRO contractors for manufacturing and testing. The TTM revenue growth YoY chart visualizes this process, where 13.70 captures a new level. Risks are linked to fibrosis therapy uncertainty and regulation. However, expansion into China and the potential of the US market create significant prospects for long-term demand growth.
Gyre Therapeutics, Inc. - פילוחים אנליטיים ומדדי מפתח (GYRE)

The commercialization of Hydronidone in China generates the primary cash flow, converting the operational successes of Gyre Therapeutics, Inc. (GYRE) into measurable financial results. By analyzing year-over-year sales dynamics over the last four quarters, investors track the percentage change in revenue on a trailing twelve months (TTM) rolling basis, which allows for the rapid identification of revenue acceleration and the filtering out of one-time spikes to confirm the sustainability of the asset's long-term trend.